Workflow
Sanofi CEO Paul Hudson on Q2 results, Dupixent demand and tariff impact
SanofiSanofi(US:SNY) CNBC Televisionยท2025-07-31 12:33

today. Thanks. >> Good.Thank you. >> Okay. >> All right.Shares of Sanofi are lower this morning. The French pharmaceutical giant second quarter profits missed estimates but revenue topped expectations. The company is also raising its annual sales forecast on strong demand from its anti-inflammatory drug, Dupixent.That stock right now off by about 4%. Joining us right now to break it all down is Paul Hudson. He's Sanofi's CEO.And Paul, I have to say reading through the results, I was a little surprised to se ...